These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27070052)

  • 21. Prescription Opioid Misuse, Abuse, Morbidity, and Mortality: Balancing Effective Pain Management and Safety.
    Cheatle MD
    Pain Med; 2015 Oct; 16 Suppl 1():S3-8. PubMed ID: 26360931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long- or short-acting opioids for chronic non-malignant pain? A qualitative systematic review.
    Pedersen L; Borchgrevink PC; Riphagen II; Fredheim OM
    Acta Anaesthesiol Scand; 2014 Apr; 58(4):390-401. PubMed ID: 24617618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioid tolerance and clinically recognized opioid poisoning among patients prescribed extended-release long-acting opioids.
    Young JC; Lund JL; Dasgupta N; Jonsson Funk M
    Pharmacoepidemiol Drug Saf; 2019 Jan; 28(1):39-47. PubMed ID: 29888409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. General pharmacology of long-acting, extended-release, and sustained-release opioids for the treatment of chronic nonmalignant pain.
    Davis MP; Gamier P; Sloan PA
    J Opioid Manag; 2015; Suppl():11-20. PubMed ID: 25539289
    [No Abstract]   [Full Text] [Related]  

  • 25. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Morphine sulfate abuse-deterrent formulations for the treatment of chronic pain.
    Fanelli A; Sorella MC; Ghisi D
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1157-1162. PubMed ID: 30403896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioid Use and Overdose: What We've Learned in Ontario.
    Gomes T; Juurlink DN
    Healthc Q; 2016; 18(4):8-11. PubMed ID: 27009700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid addiction, diversion, and abuse in chronic and cancer pain.
    Kata V; Novitch MB; Jones MR; Anyama BO; Helander EM; Kaye AD
    Curr Opin Support Palliat Care; 2018 Jun; 12(2):124-130. PubMed ID: 29465470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain.
    Taber L; Lynch SY; He E; Ripa SR
    Postgrad Med; 2016 Jan; 128(1):23-33. PubMed ID: 26681111
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescription Drug and Alcohol Use Disorders: Safe Prescribing of Opioids.
    Shin T
    FP Essent; 2019 Mar; 478():11-18. PubMed ID: 30844220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
    Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
    J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop.
    Chou R; Turner JA; Devine EB; Hansen RN; Sullivan SD; Blazina I; Dana T; Bougatsos C; Deyo RA
    Ann Intern Med; 2015 Feb; 162(4):276-86. PubMed ID: 25581257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The implications of tamper-resistant formulations for opioid rotation.
    Pappagallo M; Sokolowska M
    Postgrad Med; 2012 Sep; 124(5):101-9. PubMed ID: 23095430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic pain treatment with opioid analgesics: benefits versus harms of long-term therapy.
    Sehgal N; Colson J; Smith HS
    Expert Rev Neurother; 2013 Nov; 13(11):1201-20. PubMed ID: 24175722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Managing co-occurring substance use and pain disorders.
    Miotto K; Kaufman A; Kong A; Jun G; Schwartz J
    Psychiatr Clin North Am; 2012 Jun; 35(2):393-409. PubMed ID: 22640762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Weak" opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphine.
    Prescrire Int; 2016 Feb; 25(168):45-50. PubMed ID: 27042732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opioids for chronic noncancer pain: still no evidence for superiority of sustained-release opioids.
    Pedersen L; Fredheim O
    Clin Pharmacol Ther; 2015 Feb; 97(2):114-5. PubMed ID: 25670511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 12-Month safety and effectiveness of once-daily hydrocodone tablets formulated with abuse-deterrent properties in patients with moderate to severe chronic pain.
    Wen W; Taber L; Lynch SY; He E; Ripa S
    J Opioid Manag; 2015; 11(4):339-56. PubMed ID: 26312961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond.
    Ruan X
    Expert Opin Pharmacother; 2011 May; 12(7):999-1001. PubMed ID: 21470064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.